Valeant Appoints Thomas Ross As Lead Independent Director

(RTTNews) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced that it appointed Thomas Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board's Nominating and Corporate Governance Committee and is Chairperson of its Conduct and Compliance Committee.

Following today's Annual Meeting of Shareholders, three new independent directors were elected to Valeant's Board, including: Argeris Karabelas, Russel Robertson and Dr. Amy Wechsler. Eight directors were re-elected -- Mr. Ross, William Ackman, Frederic Eshelman, Stephen Fraidin, Robert Hale, Robert Ingram, Robert Power and Joseph Papa.

In the past year, Valeant has significantly refreshed its Board, adding nine new directors and expanding the number of independent directors to 10 out of 11.

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2017 annual meeting of shareholders.